Rohit Tripathi, VP of Industry Strategy at RELEX, talks with Pharmaceutical Executive about the impact new phased tariffs will have on reshoring pharma manufacturing.
Rohit Tripathi
Advertisement
Rohit Tripathi, VP of Industry Strategy, Consumer Packaged Goods and Manufacturing at RELEX. He specializes in supply chain operations, business transformation and applying AI to improve planning, resilience and operational performance. With more than 25 years of global experience across the U.S., India, Brazil and Europe, Rohit has led international teams delivering AI-enabled solutions for supply chain, IoT and customer experience.
Articles by Rohit Tripathi
Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy is producing structural change.
Rohit Tripathi, VP of Industry Strategy at RELEX, talks about who will actually pay for the phased tariff-driven cost increases.
Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not just domestic final assembly.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report
2
Your Questions Answered: The Biggest Pharma and Biotech Stories This Week
3
Ultragenyx Shares Drop Following Failed Phase III Clinical Trial
4
Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTech Partnership, RedHill Acquires Commercialization Rights to Rebyota & Clenpiq
5